Immunotherapy for glioblastoma: the devil is in the details.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

9 citing papers in PubMed.

1. Distribution and favorable prognostic implication of genomic EGFR alterations in IDH-wildtype glioblastoma.Cancer medicine · 2023
   Article
2. Immunotherapy for cancer in the central nervous system: Current and future directions.Oncoimmunology · 2016
   Review
3. Dendritic Cell-Based Vaccines that Utilize Myeloid Rather than Plasmacytoid Cells Offer a Superior Survival Advantage in Malignant Glioma.Journal of immunology (Baltimore, Md. : 1950) · 2015
   Article
4. Immunotherapy for brain cancer: recent progress and future promise.Clinical cancer research : an official journal of the American Association for Cancer Research · 2014
   Review
5. Heme oxygenase-1 protects regulatory T cells from hypoxia-induced cellular stress in an experimental mouse brain tumor model.Journal of neuroimmunology · 2014
   Article
6. Rindopepimut: a promising immunotherapeutic for the treatment of glioblastoma multiforme.Immunotherapy · 2014
   Review
7. Rindopepimut: anti-EGFRvIII peptide vaccine, oncolytic.Drugs of the future · 2013
   Article
8. Vaccine strategies for glioblastoma: progress and future directions.Immunotherapy · 2013
   Review
9. Fire in the Smoke: Battling Brain Tumors.Cerebrum : the Dana forum on brain science
   Article

Corrections and comments

• Comment on
  Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma.2010

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as